S&P 500   3,941.26 (-1.44%)
DOW   33,596.34 (-1.03%)
QQQ   281.68 (-2.07%)
AAPL   142.91 (-2.54%)
MSFT   245.12 (-2.03%)
META   114.12 (-6.79%)
GOOGL   96.98 (-2.51%)
AMZN   88.25 (-3.03%)
TSLA   179.82 (-1.44%)
NVDA   159.87 (-3.75%)
NIO   13.24 (+3.44%)
BABA   91.45 (+1.03%)
AMD   70.27 (-4.55%)
T   19.17 (+2.24%)
MU   53.68 (-0.67%)
CGC   3.61 (-16.44%)
F   13.28 (-0.75%)
GE   85.28 (+0.73%)
DIS   92.29 (-3.79%)
AMC   6.75 (-9.40%)
PYPL   72.23 (-1.89%)
PFE   49.71 (-2.01%)
NFLX   305.56 (-2.25%)
S&P 500   3,941.26 (-1.44%)
DOW   33,596.34 (-1.03%)
QQQ   281.68 (-2.07%)
AAPL   142.91 (-2.54%)
MSFT   245.12 (-2.03%)
META   114.12 (-6.79%)
GOOGL   96.98 (-2.51%)
AMZN   88.25 (-3.03%)
TSLA   179.82 (-1.44%)
NVDA   159.87 (-3.75%)
NIO   13.24 (+3.44%)
BABA   91.45 (+1.03%)
AMD   70.27 (-4.55%)
T   19.17 (+2.24%)
MU   53.68 (-0.67%)
CGC   3.61 (-16.44%)
F   13.28 (-0.75%)
GE   85.28 (+0.73%)
DIS   92.29 (-3.79%)
AMC   6.75 (-9.40%)
PYPL   72.23 (-1.89%)
PFE   49.71 (-2.01%)
NFLX   305.56 (-2.25%)
S&P 500   3,941.26 (-1.44%)
DOW   33,596.34 (-1.03%)
QQQ   281.68 (-2.07%)
AAPL   142.91 (-2.54%)
MSFT   245.12 (-2.03%)
META   114.12 (-6.79%)
GOOGL   96.98 (-2.51%)
AMZN   88.25 (-3.03%)
TSLA   179.82 (-1.44%)
NVDA   159.87 (-3.75%)
NIO   13.24 (+3.44%)
BABA   91.45 (+1.03%)
AMD   70.27 (-4.55%)
T   19.17 (+2.24%)
MU   53.68 (-0.67%)
CGC   3.61 (-16.44%)
F   13.28 (-0.75%)
GE   85.28 (+0.73%)
DIS   92.29 (-3.79%)
AMC   6.75 (-9.40%)
PYPL   72.23 (-1.89%)
PFE   49.71 (-2.01%)
NFLX   305.56 (-2.25%)
S&P 500   3,941.26 (-1.44%)
DOW   33,596.34 (-1.03%)
QQQ   281.68 (-2.07%)
AAPL   142.91 (-2.54%)
MSFT   245.12 (-2.03%)
META   114.12 (-6.79%)
GOOGL   96.98 (-2.51%)
AMZN   88.25 (-3.03%)
TSLA   179.82 (-1.44%)
NVDA   159.87 (-3.75%)
NIO   13.24 (+3.44%)
BABA   91.45 (+1.03%)
AMD   70.27 (-4.55%)
T   19.17 (+2.24%)
MU   53.68 (-0.67%)
CGC   3.61 (-16.44%)
F   13.28 (-0.75%)
GE   85.28 (+0.73%)
DIS   92.29 (-3.79%)
AMC   6.75 (-9.40%)
PYPL   72.23 (-1.89%)
PFE   49.71 (-2.01%)
NFLX   305.56 (-2.25%)
NASDAQ:SAVA

Cassava Sciences - SAVA Stock Forecast, Price & News

$33.62
-0.12 (-0.36%)
(As of 12/6/2022 12:00 AM ET)
Add
Compare
Today's Range
$33.12
$35.28
50-Day Range
$32.61
$46.18
52-Week Range
$13.84
$62.49
Volume
976,630 shs
Average Volume
2.12 million shs
Market Capitalization
$1.35 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$27.50

Cassava Sciences MarketRank™ Forecast

Analyst Rating
Hold
2.00 Rating Score
Upside/​Downside
18.2% Downside
$27.50 Price Target
Short Interest
Healthy
23.83% of Float Sold Short
Dividend Strength
N/A
Sustainability
-0.82
Upright™ Environmental Score
News Sentiment
0.22mentions of Cassava Sciences in the last 14 days
Based on 10 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($1.98) to ($1.29) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.57 out of 5 stars

Medical Sector

916th out of 1,023 stocks

Pharmaceutical Preparations Industry

448th out of 501 stocks

SAVA stock logo

About Cassava Sciences (NASDAQ:SAVA) Stock

Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2b clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's disease. The company was formerly known as Pain Therapeutics, Inc. and changed its name to Cassava Sciences, Inc. in March 2019. Cassava Sciences, Inc. was incorporated in 1998 and is based in Austin, Texas.

Receive SAVA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Cassava Sciences and its competitors with MarketBeat's FREE daily newsletter.

SAVA Stock News Headlines

Cassava Sciences (NASDAQ:SAVA) PT Lowered to $11.00
Cassava: Risk/Reward Equation Is More Balanced, Says Analyst
Why Is Cassava Sciences (SAVA) Stock Up Today?
CASSAVA SCIENCES INVESTIGATION CONTINUED by...
Cassava Sciences: Q3 Earnings Insights
Why Is Cassava Sciences (SAVA) Stock Down 10% Today?
Cassava Sciences Announces Expansion of Leadership Team
See More Headlines
Receive SAVA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Cassava Sciences and its competitors with MarketBeat's FREE daily newsletter.

SAVA Company Calendar

Last Earnings
11/07/2022
Today
12/06/2022
Fiscal Year End
12/31/2022
Next Earnings (Estimated)
2/27/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:SAVA
Employees
24
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$27.50
High Stock Price Forecast
$44.00
Low Stock Price Forecast
$11.00
Forecasted Upside/Downside
-18.2%
Consensus Rating
Hold
Rating Score (0-4)
2.00
Research Coverage
3 Analysts

Profitability

Net Income
$-32,380,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$6.35 per share

Miscellaneous

Free Float
36,022,000
Market Cap
$1.35 billion
Optionable
Not Optionable
Beta
0.01

Key Executives

  • Mr. Remi Barbier (Age 62)
    Founder, Chairman, Pres & CEO
    Comp: $1.74M
  • Mr. Eric J. Schoen (Age 54)
    Chief Financial Officer
    Comp: $776.93k
  • Dr. Nadav Friedmann M.D. (Age 79)
    Ph.D., Chief Medical Officer & Director
    Comp: $765k
  • Dr. James W. Kupiec M.D.
    Chief Clinical Devel. Officer
  • Dr. George Thornton
    Sr. VP of Technology
  • Mr. Michael Zamloot
    Sr. VP of Technical Operations
  • Dr. Lindsay H. Burns Ph.D.
    Sr. VP of Neuroscience













SAVA Stock - Frequently Asked Questions

Should I buy or sell Cassava Sciences stock right now?

3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Cassava Sciences in the last twelve months. There are currently 1 sell rating, 1 hold rating and 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" SAVA shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in SAVA, but not buy additional shares or sell existing shares.
View SAVA analyst ratings
or view top-rated stocks.

What is Cassava Sciences' stock price forecast for 2023?

3 Wall Street research analysts have issued 12 month target prices for Cassava Sciences' shares. Their SAVA share price forecasts range from $11.00 to $44.00. On average, they expect the company's stock price to reach $27.50 in the next twelve months. This suggests that the stock has a possible downside of 18.1%.
View analysts price targets for SAVA
or view top-rated stocks among Wall Street analysts.

How have SAVA shares performed in 2022?

Cassava Sciences' stock was trading at $43.70 at the beginning of 2022. Since then, SAVA stock has decreased by 23.2% and is now trading at $33.57.
View the best growth stocks for 2022 here
.

When is Cassava Sciences' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, February 27th 2023.
View our SAVA earnings forecast
.

How were Cassava Sciences' earnings last quarter?

Cassava Sciences, Inc. (NASDAQ:SAVA) posted its quarterly earnings data on Monday, November, 7th. The company reported ($0.51) earnings per share for the quarter, missing analysts' consensus estimates of ($0.47) by $0.04.

When did Cassava Sciences' stock split?

Shares of Cassava Sciences reverse split before market open on Wednesday, May 10th 2017. The 1-7 reverse split was announced on Monday, May 8th 2017. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, May 9th 2017. An investor that had 100 shares of stock prior to the reverse split would have 14 shares after the split.

What other stocks do shareholders of Cassava Sciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Cassava Sciences investors own include Inovio Pharmaceuticals (INO), NVIDIA (NVDA), Novavax (NVAX), Sorrento Therapeutics (SRNE), Advanced Micro Devices (AMD), NIO (NIO), DURECT (DRRX), Tesla (TSLA), OPKO Health (OPK) and Alibaba Group (BABA).

What is Cassava Sciences' stock symbol?

Cassava Sciences trades on the NASDAQ under the ticker symbol "SAVA."

Who are Cassava Sciences' major shareholders?

Cassava Sciences' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (6.20%), Vanguard Group Inc. (5.27%), State Street Corp (2.49%), Citadel Advisors LLC (0.00%), Simplex Trading LLC (0.00%) and IMC Chicago LLC (0.00%). Insiders that own company stock include Eric Schoen, James William Kupiec, Remi Barbier, Richard Barry and Sanford Robertson.
View institutional ownership trends
.

How do I buy shares of Cassava Sciences?

Shares of SAVA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Cassava Sciences' stock price today?

One share of SAVA stock can currently be purchased for approximately $33.57.

How much money does Cassava Sciences make?

Cassava Sciences (NASDAQ:SAVA) has a market capitalization of $1.35 billion. The company earns $-32,380,000.00 in net income (profit) each year or ($1.78) on an earnings per share basis.

How can I contact Cassava Sciences?

Cassava Sciences' mailing address is 7801 N CAPITAL OF TEXAS HIGHWAY SUITE 260, AUSTIN TX, 78731. The official website for the company is www.cassavasciences.com. The company can be reached via phone at (512) 501-2444, via email at ir@paintrials.com, or via fax at 512-501-0414.

This page (NASDAQ:SAVA) was last updated on 12/6/2022 by MarketBeat.com Staff